Avista, a New York-based private equity firm focused on healthcare, and Hamilton Lane, a global private markets investment management firm, have announced that funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals...
In a resounding declaration of commitment to women’s health, Discovery Park, Kent’s well-known life science and innovation community, has unveiled its latest cohort of trailblazing FemTech start-ups.
Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
In the State of the Union address earlier this year, President Biden urged U.S. lawmakers to cap insulin prices at $35 a month, an expansion of the 2022 Inflation Reduction Act. The act contains language that would allow the government to negotiate drug...
Helmholtz Munich, one of Germany’s 19 research centers, that develops future solutions and technologies has selected DataDirect Networks (DDN) to accelerate its artificial intelligence (AI) driven discoveries.
The group has introduced a downloadable guide, interactive quiz, and other tools to inform patients from underrepresented communities about trial participation.
Leaders from the R&D tech company weigh in on how use of artificial intelligence has grown, ongoing challenges to effective adoption, and what lies ahead.
A leader from the life-science organization discusses how collaboration could lead to a broad range of benefits for everyone along the drug discovery pipeline
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
The company’s Azzur Cleanrooms on Demand division has established another facility in Vista, a city in the San Diego Area, for life-sciences operations.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.
The IQVIA and NORD study shows rare-disease treatments account for only 11% of new drug spending, but 80% of orphan products treat rare diseases alone.
With demand for fast-tracking therapies, vaccines and other products increasing, companies like Azzur Group offer the ability to add capabilities quickly.
Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an expert from the CRO.
Intelligent Tissue Group has launched its Intelligent Clinical trials facility to help assess the effectiveness and safety of potential new treatments.
This year the conference brings its content, focused on the intersection of clinical research and patient care, from the real world to the virtual one.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.
Speaking at the FT Pharmaceutical & Biotechnology conference earlier this week, Ipsen’s CCO said that pharma manufacturers need to focus more on the ‘why’.
Rosalind Franklin University of Medicine and Science opens its incubator, Helix 51, creating wet lab and research space for the Illinois bioscience hub.
Evotec is partnering with a global non-profit research group to develop a pipeline of novel antibiotics after integrating Sanofi’s infectious disease unit last year.
Key Biologics and Cascade Regional Blood Services’ multi-year agreement will provide researchers with the critical raw material needed for developing cell- and gene-based therapies.
Genetic discoveries have taken place in narrow population groups, say researchers, who for the first time, reveal that such studies are concentrated in a handful of countries – and conducted by a ‘tight-knit group of researchers.’
Upperton Pharma’s new and expanded facilities received a positive inspection from MHRA, enabling both research and development and clinical manufacturing at the site.
SPARC and Schrödinger will collaborate to use Schrödinger’s technological platforms and SPARC’s insights into research therapeutics for neurodegenerative conditions.
Yale University is partnering with CROs to provide drug discovery services to awardees of the Blavatnik Fund for Innovation – which aims to bridge the gap between early-stage research and product development.
Velesco Pharma has expanded its analytical research and development capabilities to meet a growing demand for its services after acquiring a new facility in Michigan.
The companies announced a partnership to integrate 4G’s technology with Clarkston’s clinical supply chain services in an aim to enrich clinical trial strategy and operations.
The platform will be designed to help life sciences organizations improve productivity, efficiency, and innovation in early stage drug development, says Accenture executive.
The Nuvisan Group is taking on part of Galderma’s R&D capacities site, growing its service lines in bioanalysis, clinical trial supplies, and pharmaceutical analytics
